Credit: Shutterstock photoXOMA Corporation ( XOMA ) recently progressed with its pipeline candidate gevokizumab. XOMA announced that it has completed enrolling patients in a phase II proof-of-concept study (n=90) on gevokizumab (60 mg).
Gevokizumab is being developed to improve pain symptoms, physical function and structural abnormalities in patients suffering from active inflammatory, erosive osteoarthritis of the hand (EOA) and elevated C-reactive protein (CRP) levels. The patients enrolled in the study were randomized 2:1 to receive gevokizumab dosed subcutaneously once monthly or placebo.
The study will also evaluate multiple outcome measures, including pain, stiffness, physical function, X-ray, radiographic and MRI changes. XOMA intends to reveal preliminary top-line data from the study in Oct 2013.
We note that last month XOMA along with partner, Servier, launched a proof-of-concept clinical program for the development of gevokizumab. XOMA and Servier are evaluating the use of gevokizumab in a number of indications including non-infectious uveitis (NIU) involving the intermediate and/or posterior portion of the eye and Behçet's uveitis.
The candidate is also being assessed for inflammatory acne in a phase II proof-of-concept study. In Jan 2013, preliminary top-line data from the study was reported following an interim analysis.
Moreover, in Jun 2013, XOMA initiated a pilot study to evaluate the use of gevokizumab in patients suffering from acute inflammatory pyoderma gangrenosum, a form of neutrophilic dermatoses.
XOMA carries a Zacks Rank #3 (Hold). Companies that currently look attractive include Jazz Pharmaceuticals ( JAZZ ), Sarepta Therapeutics, Inc. ( SRPT ) and Cadence Pharmaceuticals Inc. ( CADX ). All the three carry a Zacks Rank #1 (Strong Buy).
CADENCE PHARMA (CADX): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
SAREPTA THERAP (SRPT): Free Stock Analysis Report
XOMA CORP (XOMA): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
